Research programme: stem cell therapies - Celogos

Drug Profile

Research programme: stem cell therapies - Celogos

Alternative Names: AlloCell; Allogenic project

Latest Information Update: 24 Jul 2006

Price : $50

At a glance

  • Originator Celogos
  • Class Stem cell therapies
  • Mechanism of Action Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cardiovascular disorders; Musculoskeletal disorders

Most Recent Events

  • 24 Jul 2006 Preclinical trials in Cardiovascular disorders in France (Parenteral)
  • 24 Jul 2006 Preclinical trials in Musculoskeletal disorders in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top